Opko Health Inc (OPK) 9.76 $OPK OPKO to Present
Post# of 273243
Posted On: 09/08/2016 11:14:35 AM
Opko Health Inc (OPK) 9.76 $OPK
OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology
BusinessWire - Tue Sep 06, 7:30AM CDT
OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016.
OPK: 9.76 (+0.17)
Cocrystal Pharma Receives Investment Through Private Placement
Marketwired - Fri Sep 02, 7:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - September 02, 2016) - On September 1, 2016, Cocrystal Pharma, Inc. (OTCQB: COCP) (the "Company"
closed on proceeds of $4,008,201 in a private placement offering (the "Offering" of 9,776,100 shares of the Company's common stock at a purchase price of $0.41 per share. The purchasers included three members of the Company's board of directors, including Chairman Dr. Raymond F. Schinazi, Interim Chief Executive Officer Dr. Gary Wilcox, and Dr. David Block. In addition, OPKO Health, Inc., of which the Company's director Dr. Phillip Frost is Chairman and Chief Executive Officer, invested in the Offering.
OPK: 9.76 (+0.17)
OPKO Health to Participate in Upcoming September Conferences
BusinessWire - Thu Sep 01, 3:43PM CDT
OPKO Health, Inc. (Nasdaq: OPK), today announced that senior management will participate in the 11th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9th Annual Barrington Research Fall Investment Conference taking place on September 8, 2016 in Chicago.
OPK: 9.76 (+0.17), WFC: 49.73 (-0.04)
SmarTrend Watching for Potential Pullback in Shares of Opko Health After 1.32% Gain
Comtex SmarTrend(R) - Thu Sep 01, 2:59PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $9.20 to a high of $9.54. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $9.46 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 9.76 (+0.17)
InvestorsObserver releases covered-call reports for Freeport-McMoRan, Potash Corporation of Saskatchewan, Smith & Wesson, JetBlue and Opko Health
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCX, JBLU, OPK, POT, and SWHC.
OPK: 9.76 (+0.17), FCX: 10.46 (-0.14), POT: 17.40 (-0.26), JBLU: 16.70 (-0.03), SWHC: 27.83 (-0.20)
OPKO Health Completes Acquisition of Transition Therapeutics
BusinessWire - Wed Aug 31, 12:00AM CDT
OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (NASDAQ: TTHI, TSX: TTH), by way of a plan of arrangement (the "Arrangement" which was approved by Transition Therapeutics' shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of Transition Therapeutics. The Arrangement was approved by the Ontario Superior Court of Justice in its final order dated August 29, 2016.
TTH.TO: 1.93 (+0.01), OPK: 9.76 (+0.17), TTHI: 1.52 (unch)
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
BusinessWire - Fri Aug 26, 7:52AM CDT
OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. (NASDAQ:TTHI, TSX: TTH) holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics. The acquisition is subject to final approval of the Ontario Superior Court Justice (the "Court". The Court hearing for the final order is scheduled to take place on August 29, 2016, and the acquisition is expected to close on September 1, 2016.
TTH.TO: 1.93 (+0.01), OPK: 9.76 (+0.17), TTHI: 1.52 (unch)
Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 9.76 (+0.17), SRPT: 28.16 (-0.30), MNKD: 0.73 (+0.02), CELG: 106.99 (+0.03), CELGZ: 1.20 (-0.05)
Look for Shares of Opko Health to Potentially Rebound after Yesterday's 2.96% Sell Off
Comtex SmarTrend(R) - Tue Aug 23, 3:19PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $9.37 to a high of $9.91. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $9.70 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
OPK: 9.76 (+0.17)
OPKO Health Responds to Law Firm Notice of Investigation
BusinessWire - Tue Aug 23, 11:46AM CDT
OPKO Health, Inc. (NYSE:OPK), is aware of a press release by Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it is investigating the Company for an alleged potential breach of fiduciary duty claim involving the Company's Board of Directors. The Company has not received any notification or information from Purcell Julie & Lefkowitz regarding its investigation of any potential breach of fiduciary duty or other claim against OPKO's Board of Directors. Nor have any such claims or allegations been made by any shareholders, other law firms or regulatory bodies. OPKO's attempts to contact the law firm have gone unanswered. The Company does not believe there is any basis or merit behind the investigation and will vigorously defend itself should any formal allegations or claims be made.
OPK: 9.76 (+0.17)
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP(R) Cell Therapy System for the Treatment of Heart Failure
BusinessWire - Tue Aug 23, 7:34AM CDT
BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, announced today that it has entered into a definitive agreement to merge with Tiger X Medical, Inc. (OTCPink: CDOM). The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia.
OPK: 9.76 (+0.17), BCDA: ()
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating OPKO Health, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 23, 6:10AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of OPKO Health, Inc. (NASDAQ: OPK).
OPK: 9.76 (+0.17)
Arno Completes $2.8 Million Private Placement
BusinessWire - Tue Aug 16, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock and common stock purchase warrants that will result resulting in gross proceeds to the Company of approximately $2.8 million. The financing was led by the Company's existing investors, including affiliates of Chairman, Arie Belldegrun, MD, OPKO Health, Inc., Commercial Street Capital LLC, Pontifax, Bonderman Family Limited Partnership, Perceptive Advisors LLC and Auriga Capital Management. The Company intends to use the proceeds from this financing to fund its ongoing clinical development of onapristone, its lead product candidate, and for general corporate purposes.
OPK: 9.76 (+0.17)
Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets
BusinessWire - Fri Aug 12, 9:59AM CDT
Research and Markets has announced the addition of the "Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Review, H1 2016" report to their offering.
OPK: 9.76 (+0.17), CELGZ: 1.20 (-0.05)
Facebook, Opko Health, ZELTIQ Aesthetics, Palo Alto Networks, and Yelp and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FB, OPK, PANW, YELP, and ZLTQ.
ZLTQ: 38.45 (-0.13), OPK: 9.76 (+0.17), FB: 130.24 (-0.81), YELP: 38.58 (-0.47), PANW: 147.57 (+0.24)
Cocrystal Pharma Announces Filing 2016 Second Quarter Financial Statements and Provides Company Update
Marketwired - Wed Aug 10, 5:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - August 10, 2016) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending June 30, 2016 and provided an update on its pre-clinical and clinical programs.
OPK: 9.76 (+0.17)
Opko Health Set to Possibly Pullback After Yesterday's Rally of 1.62%
Comtex SmarTrend(R) - Tue Aug 09, 3:42PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $10.16 to a high of $10.54. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $10.22 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 9.76 (+0.17)
Here's 5 Medical Stocks Soaring After Earnings Today
Ryan McQueeney - Zacks Investment Research - Tue Aug 09, 1:36PM CDT
Check out these five medical-related companies that are in the green following their most recent reports.
ENDP: 20.47 (+0.17), ICUI: 128.05 (+0.47), VRX: 29.99 (-0.28), OPK: 9.76 (+0.17), NVRO: 99.00 (+0.39)
OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology
BusinessWire - Tue Sep 06, 7:30AM CDT
OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016.
OPK: 9.76 (+0.17)
Cocrystal Pharma Receives Investment Through Private Placement
Marketwired - Fri Sep 02, 7:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - September 02, 2016) - On September 1, 2016, Cocrystal Pharma, Inc. (OTCQB: COCP) (the "Company"
closed on proceeds of $4,008,201 in a private placement offering (the "Offering" of 9,776,100 shares of the Company's common stock at a purchase price of $0.41 per share. The purchasers included three members of the Company's board of directors, including Chairman Dr. Raymond F. Schinazi, Interim Chief Executive Officer Dr. Gary Wilcox, and Dr. David Block. In addition, OPKO Health, Inc., of which the Company's director Dr. Phillip Frost is Chairman and Chief Executive Officer, invested in the Offering. OPK: 9.76 (+0.17)
OPKO Health to Participate in Upcoming September Conferences
BusinessWire - Thu Sep 01, 3:43PM CDT
OPKO Health, Inc. (Nasdaq: OPK), today announced that senior management will participate in the 11th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9th Annual Barrington Research Fall Investment Conference taking place on September 8, 2016 in Chicago.
OPK: 9.76 (+0.17), WFC: 49.73 (-0.04)
SmarTrend Watching for Potential Pullback in Shares of Opko Health After 1.32% Gain
Comtex SmarTrend(R) - Thu Sep 01, 2:59PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $9.20 to a high of $9.54. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $9.46 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 9.76 (+0.17)
InvestorsObserver releases covered-call reports for Freeport-McMoRan, Potash Corporation of Saskatchewan, Smith & Wesson, JetBlue and Opko Health
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCX, JBLU, OPK, POT, and SWHC.
OPK: 9.76 (+0.17), FCX: 10.46 (-0.14), POT: 17.40 (-0.26), JBLU: 16.70 (-0.03), SWHC: 27.83 (-0.20)
OPKO Health Completes Acquisition of Transition Therapeutics
BusinessWire - Wed Aug 31, 12:00AM CDT
OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (NASDAQ: TTHI, TSX: TTH), by way of a plan of arrangement (the "Arrangement"
which was approved by Transition Therapeutics' shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of Transition Therapeutics. The Arrangement was approved by the Ontario Superior Court of Justice in its final order dated August 29, 2016. TTH.TO: 1.93 (+0.01), OPK: 9.76 (+0.17), TTHI: 1.52 (unch)
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
BusinessWire - Fri Aug 26, 7:52AM CDT
OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. (NASDAQ:TTHI, TSX: TTH) holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics. The acquisition is subject to final approval of the Ontario Superior Court Justice (the "Court"
. The Court hearing for the final order is scheduled to take place on August 29, 2016, and the acquisition is expected to close on September 1, 2016. TTH.TO: 1.93 (+0.01), OPK: 9.76 (+0.17), TTHI: 1.52 (unch)
Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 9.76 (+0.17), SRPT: 28.16 (-0.30), MNKD: 0.73 (+0.02), CELG: 106.99 (+0.03), CELGZ: 1.20 (-0.05)
Look for Shares of Opko Health to Potentially Rebound after Yesterday's 2.96% Sell Off
Comtex SmarTrend(R) - Tue Aug 23, 3:19PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $9.37 to a high of $9.91. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $9.70 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
OPK: 9.76 (+0.17)
OPKO Health Responds to Law Firm Notice of Investigation
BusinessWire - Tue Aug 23, 11:46AM CDT
OPKO Health, Inc. (NYSE:OPK), is aware of a press release by Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it is investigating the Company for an alleged potential breach of fiduciary duty claim involving the Company's Board of Directors. The Company has not received any notification or information from Purcell Julie & Lefkowitz regarding its investigation of any potential breach of fiduciary duty or other claim against OPKO's Board of Directors. Nor have any such claims or allegations been made by any shareholders, other law firms or regulatory bodies. OPKO's attempts to contact the law firm have gone unanswered. The Company does not believe there is any basis or merit behind the investigation and will vigorously defend itself should any formal allegations or claims be made.
OPK: 9.76 (+0.17)
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP(R) Cell Therapy System for the Treatment of Heart Failure
BusinessWire - Tue Aug 23, 7:34AM CDT
BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, announced today that it has entered into a definitive agreement to merge with Tiger X Medical, Inc. (OTCPink: CDOM). The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia.
OPK: 9.76 (+0.17), BCDA: ()
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating OPKO Health, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 23, 6:10AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of OPKO Health, Inc. (NASDAQ: OPK).
OPK: 9.76 (+0.17)
Arno Completes $2.8 Million Private Placement
BusinessWire - Tue Aug 16, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock and common stock purchase warrants that will result resulting in gross proceeds to the Company of approximately $2.8 million. The financing was led by the Company's existing investors, including affiliates of Chairman, Arie Belldegrun, MD, OPKO Health, Inc., Commercial Street Capital LLC, Pontifax, Bonderman Family Limited Partnership, Perceptive Advisors LLC and Auriga Capital Management. The Company intends to use the proceeds from this financing to fund its ongoing clinical development of onapristone, its lead product candidate, and for general corporate purposes.
OPK: 9.76 (+0.17)
Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets
BusinessWire - Fri Aug 12, 9:59AM CDT
Research and Markets has announced the addition of the "Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Review, H1 2016" report to their offering.
OPK: 9.76 (+0.17), CELGZ: 1.20 (-0.05)
Facebook, Opko Health, ZELTIQ Aesthetics, Palo Alto Networks, and Yelp and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FB, OPK, PANW, YELP, and ZLTQ.
ZLTQ: 38.45 (-0.13), OPK: 9.76 (+0.17), FB: 130.24 (-0.81), YELP: 38.58 (-0.47), PANW: 147.57 (+0.24)
Cocrystal Pharma Announces Filing 2016 Second Quarter Financial Statements and Provides Company Update
Marketwired - Wed Aug 10, 5:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - August 10, 2016) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending June 30, 2016 and provided an update on its pre-clinical and clinical programs.
OPK: 9.76 (+0.17)
Opko Health Set to Possibly Pullback After Yesterday's Rally of 1.62%
Comtex SmarTrend(R) - Tue Aug 09, 3:42PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $10.16 to a high of $10.54. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $10.22 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 9.76 (+0.17)
Here's 5 Medical Stocks Soaring After Earnings Today
Ryan McQueeney - Zacks Investment Research - Tue Aug 09, 1:36PM CDT
Check out these five medical-related companies that are in the green following their most recent reports.
ENDP: 20.47 (+0.17), ICUI: 128.05 (+0.47), VRX: 29.99 (-0.28), OPK: 9.76 (+0.17), NVRO: 99.00 (+0.39)
(0)
(0)Scroll down for more posts ▼